Investigator-Initiated Studies (IIS)
Convoca: UCB Pharma SA
Termini: 30/10/2026

Current Strategic Areas of Interest for IISs (including study review cycles):

• Rare diseases
• Epilepsy
• Immunology
• Bone

Submissions are welcomed throughout the year however there will be strict review cycles (see below).
If your study proposal is submitted during the one of three yearly review periods it will have to wait until the next review cycle to be evaluated.

• • Immunology / Bone
    1st cycle: 1 January – 31 January
    2nd cycle: 1 June – 30 June
    3rd cycle: 1 September – 30 September
  • Rare diseases / Epilepsy
    1st cycle: 1 February – 28 February
    2nd cycle: 1 July – 31 July
    3rd cycle: 1 October – 30 October